Adicet Bio Stock Analysis

Adicet Stock Analysis Notes

About 76.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.35. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adicet Bio has Price/Earnings To Growth (PEG) ratio of 0.82. The entity recorded a loss per share of 1.7. The firm last dividend was issued on the 16th of September 2020. Adicet Bio had 1:7 split on the 16th of September 2020. Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 86 people. For more info on Adicet Bio please contact BA CPA at 650 503 9095 or go to https://www.adicetbio.com.

Adicet Bio Investment Alerts

Adicet Bio Upcoming and Recent Events

Adicet Largest EPS Surprises

View All Earnings Estimates

Adicet Stock Institutional Investors

Note, although Adicet Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Adicet Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 74.16 M.

Adicet Profitablity

Management Efficiency

Adicet Bio has return on total asset (ROA) of (0.293) % which means that it has lost $0.293 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5791) %, meaning that it created substantial loss on money invested by shareholders. Adicet Bio's management efficiency ratios could be used to measure how well Adicet Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.65 in 2024. Return On Capital Employed is likely to gain to -0.77 in 2024. Total Current Liabilities is likely to drop to about 18.3 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 165.2 M in 2024

Technical Drivers

As of the 26th of November, Adicet Bio shows the Mean Deviation of 2.81, risk adjusted performance of (0.15), and Standard Deviation of 3.58. Adicet Bio technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Adicet Bio Price Movement Analysis

Adicet Bio Insider Trading Activities

Adicet Bio Outstanding Bonds

Adicet Bio Predictive Daily Indicators

Adicet Bio Forecast Models

Adicet Bio's time-series forecasting models are one of many Adicet Bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Adicet Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Adicet Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Adicet shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Adicet Bio. By using and applying Adicet Stock analysis, traders can create a robust methodology for identifying Adicet entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Adicet analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Adicet analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Adicet Bio stock analysis indicators help investors evaluate how Adicet Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Adicet Bio shares will generate the highest return on investment. By understating and applying Adicet Bio stock analysis, traders can identify Adicet Bio position entry and exit signals to maximize returns.

When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.